Lonapegsomatropin

TransCon technology attaches methoxy-PEG to somatropin through a transient linker whose cleavage rate depends only on physiological pH and temperature, not on enzymes. That makes release kinetics unusually predictable and, critically, the released molecule is unmodified 191-amino-acid somatropin with normal GH receptor binding and full-size distribution into tissues - unlike permanently modified long-acting GH analogues where target-tissue penetration is a genuine open question. Roughly 25 percent of the administered dose is released as active GH over the week, producing a serum profile that mimics daily GH dosing on a weekly cadence. IGF-1 peaks around day 2 to 3.

Targets: Growth hormone receptor (GHR), JAK2/STAT5 pathway, Hepatic IGF-1 production

• · 0.24 mg per kg of hGH once weekly for treatment-naive children. For a 25 kg child that is 6 mg weekly. Dose is expressed as hGH content, not total conjugate mass.
• · Weight-based and age-adjusted starting doses with titration against IGF-1 SDS; the adult indication was added after the paediatric approval.

Work out your exact syringe units →

• commonViral infection, pyrexia and cough in paediatric trials— Background paediatric events; incidence was comparable to daily somatropin.
• commonInjection-site reactions
• commonHeadache
• commonArthralgia and peripheral oedema— More prominent in the adult indication.
• uncommonAdrenal insufficiency unmasked— Labelled warning across the GH class.
• rareIntracranial hypertension— Fundoscopy is recommended before and periodically during treatment.
• rareSlipped capital femoral epiphysis— New hip or knee pain in a growing child needs imaging.
• rarePancreatitis— Reported across the GH class, particularly in children.

• Acute critical illness after open heart or abdominal surgery, multiple accidental trauma or acute respiratory failure.
• Closed epiphyses when treating for growth.
• Active malignancy.
• Active proliferative or severe non-proliferative diabetic retinopathy.
• Prader-Willi syndrome with severe obesity, history of airway obstruction or severe respiratory impairment.
• Known hypersensitivity to somatropin or the PEG component.

• conflictGlucocorticoids — Steroid doses may need adjusting; supraphysiological steroids also blunt growth response.
• conflictOral oestrogen — Reduces IGF-1 response to GH.
• cautioninsulin — Insulin requirements can increase.
• redundantsomatropin — This is somatropin, delivered weekly. It substitutes for daily GH rather than adding to it.

• · IGF-1 SDS at baseline and periodically, with dose adjusted to keep it within the normal range.
• · Growth velocity and bone age in children.
• · Fasting glucose and HbA1c.
• · Fundoscopic examination for intracranial hypertension.
• · Thyroid function and adrenal status.

FDA and EMA approved, prescription-only. Prohibited in sport under WADA S2.

• Thornton et al. 2021 JCEM, phase 3 trial of weekly lonapegsomatropin versus daily somatropin in paediatric GH deficiency (trial)
• Skytrofa (lonapegsomatropin-tcgd) FDA prescribing information (label)

This is the cleverest piece of pharmacology in the class and it is worth understanding why. Every other long-acting GH - somapacitan, somatrogon - is a permanently modified molecule, which raises an unavoidable question: does the bulk of the modification impair distribution into target tissues where GH receptors sit outside the vascular compartment? Growth plates, muscle, adipose. TransCon sidesteps the question entirely. The PEG carrier holds somatropin inactive, the linker cleaves by a purely chemical reaction whose rate depends only on pH and temperature, and what emerges is ordinary unmodified 191-residue somatropin with normal size, normal receptor binding and normal tissue penetration. Roughly 25 percent of the administered conjugate mass is released as active GH over the week. Because the cleavage is not enzymatic, release rate does not vary with anyone's liver, and the serum profile mimics daily GH dosing on a weekly cadence rather than producing a single spike. The pharmacokinetics in the label confirm the design worked: released somatropin has an apparent half-life of about 25 hours, tmax around 12 to 13 hours, steady-state volume of distribution 0.13 L/kg, apparent clearance 3.2 mL/h/kg in children, and no significant accumulation on repeat weekly dosing. Downstream receptor pharmacology is identical to somatropin - site 1, site 2, dimer realignment, JAK2, STAT5b, hepatic IGF-1 - because downstream it is somatropin.

The device. Skytrofa is a cartridge-and-autoinjector system with nine different strengths, and the failure modes are mechanical rather than pharmacological - wrong cartridge, incomplete delivery, a cartridge left out of refrigeration too long. There is no vial to reconstitute and no room for improvisation. The second issue is dose expression: the dose is stated as hGH content, not total conjugate mass, and confusing the two produces a fourfold error. Third, IGF-1 sampling at inconsistent points in the weekly cycle makes titration unreliable, exactly as it does with somapacitan. Fourth, the class warnings are real in the paediatric population: intracranial hypertension, slipped capital femoral epiphysis presenting as new hip or knee pain, and pancreatitis. New limp in a child on GH is an imaging question, not a wait-and-see.

1. —Paediatric, treatment-naive — 0.24 mg per kg of hGH once weekly. For a 25 kg child that is 6 mg weekly. The dose is expressed as hGH content, not as total conjugate mass, which is a distinction worth being clear about.
2. 2.1 mgAdult, under 30 or on oral oestrogen — 2.1 mg once weekly starting dose.
3. 700 mcgAdult, over 60 — 0.7 mg once weekly starting dose. Age-stratified starting doses reflect the greater GH sensitivity of older adults.
4. —Titration — Adjust against IGF-1 SDS using the specific rules in the label, sampling at a consistent point in the weekly cycle.

• Growth hormone receptor (GHR) — Identical to somatropin, because the released molecule is somatropin

  Conventional GH receptor signalling. The prodrug itself is inactive at the receptor.

• TransCon linker (chemical, not biological) — Cleavage rate governed solely by physiological pH and temperature

  Predictable enzyme-independent release of unmodified somatropin across a week. About 25 percent of administered dose is released as active GH.

• Hepatic IGF-1 production — Not applicable

  IGF-1 peaks around days 2 to 3 of the weekly cycle, which is why sampling timing matters for titration.

• heiGHt - Thornton et al., weekly lonapegsomatropin versus daily somatropin in treatment-naive children with growth hormone deficiency 3 · 52 weeks · 2021

  Annualised height velocity at 52 weeks. Per the label, 11.2 cm/year on lonapegsomatropin versus 10.3 cm/year on daily somatropin - non-inferior and numerically superior. The basis of the 2021 FDA approval.

• enliGHten - Maniatis et al., long-term extension of lonapegsomatropin in children with growth hormone deficiency 3 extension · 104 weeks · 2022

  Safety and efficacy at two years, with subsequent reporting of sustained height improvements to six years. Long-term follow-up is genuinely unusual in this class.

• fliGHt - Maniatis et al., switching to weekly lonapegsomatropin from daily somatropin in children with growth hormone deficiency 3 · 26 weeks · 2022

  Safety and efficacy of switching established patients from daily somatropin to weekly lonapegsomatropin.

Released somatropin peaks at 12 to 13 hours after injection with an apparent half-life around 25 hours, giving a week of exposure per dose and no significant accumulation between doses. IGF-1 rises within the first week and peaks around days 2 to 3 of each cycle. Growth velocity is assessed at 26 and 52 weeks in children, and the enliGHten extension followed height outcomes out to six years.

Nothing to stack. This is somatropin delivered weekly and it replaces daily GH rather than adding to it. GH secretagogues are pointless alongside it. The interaction set is the standard GH one: glucocorticoid doses may need adjusting in both directions, oral oestrogen blunts the IGF-1 response and is reflected in a higher adult starting dose, and insulin requirements may rise.

Against somapacitan and somatrogon: lonapegsomatropin's distinguishing claim is that the molecule reaching the receptor is unmodified somatropin, so questions about tissue distribution and receptor potency that apply to permanently modified analogues do not apply here. That is a genuine and elegant advantage, though whether it produces better outcomes is a network-meta-analysis question rather than a settled one. Somatrogon requires much larger milligram doses because the CTP additions add mass without potency, and has notably more injection-site reactions. Against daily somatropin: non-inferior and numerically superior on height velocity in the registration trial, at substantially higher cost, with one injection a week instead of seven. Against everything grey-market in this class: not comparable. This is one of the best-evidenced compounds in the entire corpus.

$4000–$9000/month. US list pricing for Skytrofa is among the highest in this class, running into the thousands of dollars a month and weight-dependent in children. Access is through insurance and specialty pharmacy; there is no grey market for this product. Figures are approximate.

• ?No absolute bioavailability figure is published.
• ?The 9.1 L volume of distribution here is the labelled 0.13 L/kg scaled to 70 kg rather than a directly reported litre value.
• ?The Core record does not give a molecular weight for the conjugate and none was resolved here; the figure would be dominated by the PEG carrier and varies with the specific conjugate.
• ?The 25 percent release fraction is widely reported and consistent with the design but was not confirmed against the label text retrieved in this session.
• ?Time to steady state is not stated in the label; the label reports no significant accumulation on repeat dosing, which is entered here instead.
• ?Long-term safety beyond the enliGHten follow-up period, and specifically the consequences of lifelong weekly PEG exposure in children, remains under registry observation.

• Weekly lonapegsomatropin in treatment-naive children with growth hormone deficiency: the phase 3 heiGHt trial Thornton PS, Maniatis AK, Aghajanova E, et al., Journal of Clinical Endocrinology and Metabolism, 2021 · PMID 34272849

  The registration trial.

• Safety and efficacy of lonapegsomatropin in children with growth hormone deficiency: enliGHten trial 2-year results Maniatis AK, Casella SJ, Nadgir UM, et al., Journal of Clinical Endocrinology and Metabolism, 2022 · PMID 35428884

  Two-year extension safety and efficacy.

• Switching to weekly lonapegsomatropin from daily somatropin in children with growth hormone deficiency: the fliGHt trial Maniatis AK, Nadgir U, Saenger P, et al., Hormone Research in Paediatrics, 2022 · PMID 35263755

  The switching study, which is the practically relevant question for children already on daily GH.

• SKYTROFA (lonapegsomatropin-tcgd) for injection - US prescribing information DailyMed, Ascendis Pharma

  Source of the pharmacokinetics here: released somatropin tmax 12 hours in children and 13 in adults, apparent half-life about 25 hours, steady-state volume of distribution 0.13 L/kg, apparent clearance 3.2 mL/h/kg, no significant accumulation, plus the dosing and heiGHt height velocity figures.

• Efficacy and safety of somapacitan relative to somatrogon and lonapegsomatropin in pediatric growth hormone deficiency: systematic literature review and network meta-analysis de Fries Jensen L, Antavalis V, Odgaard-Jensen J, et al., Advances in Therapy, 2024 · PMID 39261416

  Head-to-head-adjacent comparison of the three weekly GH products, which is the question anyone choosing between them actually has. Note the sponsor context when reading it.